PharmaNutra SpAMIL:PHN +0.57%86 Gross Margin % is 73.95% as of Mar. 2026, which is 1% above its 10-year median of 73.49. GuruFocus rates MIL:PHN with a GF Score™ of 86/100 and a GF Value™ of €71.41 (Modestly Overvalued). The stock has 6 warning signs investors should review. Among 935 Drug Manufacturers companies, PharmaNutra SpA ranks better than 89.09% on this metric.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
PharmaNutra SpA had a gross margin of 73.95% for the quarter that ended in Mar. 2026 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
PharmaNutra SpA Gross Margin % Related Terms
PharmaNutra SpA Gross Margin % Historical Data
* Premium members only.
The historical data trend for PharmaNutra SpA's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MIL:PHN vs ZTS, UTHR, VTRS: Gross Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, PharmaNutra SpA's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PharmaNutra SpA Gross Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, PharmaNutra SpA's Gross Margin % distribution charts can be found below:
* The bar in red indicates where PharmaNutra SpA's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
PharmaNutra SpA (MIL:PHN) has a Gross Margin % of 73.95% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on PharmaNutra SpA and its competitors. This is near median its historical median of 73.49. Over the past decade, PharmaNutra SpA's Gross Margin % has ranged from 31.79 to 77.76. According to the industry distribution chart, PharmaNutra SpA ranks #102 out of 935 companies in the Drug Manufacturers industry, placing it in the top 10.9%.
Is PharmaNutra SpA's Gross Margin % too high?
PharmaNutra SpA's current Gross Margin % of 73.95% is near median its 10-year median of 73.49. Over the past 10 years, this metric has ranged from a low of 31.79 to a high of 77.76. The Drug Manufacturers industry median Gross Margin % is 48.54. PharmaNutra SpA's value of 73.95% is 52.3% above this industry median. Based on the distribution chart, PharmaNutra SpA ranks #102 out of 935 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, PharmaNutra SpA has a GF Score™ of 86/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does PharmaNutra SpA's Gross Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, PharmaNutra SpA ranks #102 out of 935 companies for Gross Margin %. This places PharmaNutra SpA in the top 11% of its industry — outperforming the majority of peers. The industry median Gross Margin % is 48.54. PharmaNutra SpA's value of 73.95% is 52.3% above this benchmark. Historically, PharmaNutra SpA's own Gross Margin % has ranged from 31.79 to 77.76 over the past decade. While the company's 10-year median is 73.49 vs. the industry median of 48.54, PharmaNutra SpA has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Drug Manufacturers company?
The median Gross Margin % among Drug Manufacturers companies is 48.54, based on 935 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PharmaNutra SpA's current Gross Margin % of 73.95% is 52.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on PharmaNutra SpA and its competitors. For the Drug Manufacturers industry, the median Gross Margin % is 48.54 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PharmaNutra SpA's current Gross Margin % is 73.95%, which is near median its own 10-year median of 73.49. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PharmaNutra SpA stock overvalued right now?
Based on GuruFocus' analysis, PharmaNutra SpA (MIL:PHN) is currently considered Modestly Overvalued. The stock's GF Value™ is €71.41, compared to a current price of €87.70 — trading 22.8% above its estimated fair value. The current Gross Margin % is 73.95%, which is near median its 10-year median of 73.49 and 52.3% above the Drug Manufacturers industry median of 48.54. PharmaNutra SpA's overall GF Score™ is 86/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For PharmaNutra SpA (MIL:PHN), the current Gross Margin % is 73.95% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PharmaNutra SpA (MIL:PHN) Overvalued in 2026?
Based on GuruFocus' analysis, PharmaNutra SpA stock appears to be overvalued.
The current stock price of €87.70 is trading 22.8% above its estimated GF Value™ of €71.41.
GuruFocus considers PharmaNutra SpA to be Modestly Overvalued.
Key valuation signals for MIL:PHN:
Gross Margin %: 73.95% (near median its 10-year median of 73.49)
GF Value™: €71.41 vs. price of €87.70 (22.8% above fair value)
Industry Position: 52.3% above the Drug Manufacturers median (#102 of 935)
No single metric tells the full story. See the MIL:PHN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PharmaNutra SpA is a pharmaceutical company. The company is engaged in the research, design, development, and marketing of nutraceutical supplements and medical devices. The products of the company include SiderAL Folic, UltraMag, Cetilar, and others. The company operates in Europe, the Middle East, South America, the Far East, and other regions.
86GF Score
Get the complete analysis for MIL:PHN
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MIL:PHN has been successfully added to your 
